REVA Medical (RVALL) 10-Q7 Aug 142014 Q2 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2014	Aug. 01, 2014
Document and Entity Information	'	'
Entity Registrant Name	'REVA Medical, Inc.	'
Entity Central Index Key	'0001496268	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	33,459,203
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$8,979	$19,229
Short-term investments	745	1,492
Prepaid expenses and other current assets	317	415
Total current assets	10,041	21,136
Property and equipment, net	3,210	3,589
Other assets	60	60
Total Assets	13,311	24,785
Current Liabilities:	'	'
Accounts payable	702	1,400
Accrued expenses and other current liabilities	1,127	2,080
Total current liabilities	1,829	3,480
Long-term liabilities	412	480
Total Liabilities	2,241	3,960
Commitments and contingencies (Note 5)	'	'
Stockholders' Equity:	'	'
Undesignated preferred stock - $0.0001 par value; 5,000,000 shares authorized; no shares issued or outstanding	'	'
Additional paid-in capital	224,685	222,331
Deficit accumulated during the development stage	-213,618	-201,509
Total Stockholders' Equity	11,070	20,825
Total Liabilities and Stockholders' Equity	13,311	24,785
Common Class A [Member]	'	'
Stockholders' Equity:	'	'
Common stock	3	3
Common Class B [Member]	'	'
Stockholders' Equity:	'	'
Common stock	'	'

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Undesignated preferred stock, par value (in dollars per share)	$0.00	$0.00
Undesignated preferred stock, shares authorized	5,000,000	5,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common Class A [Member]	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	33,459,203	33,270,053
Common stock, shares outstanding	33,459,203	33,270,053
Common Class B [Member]	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended		193 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Operating Expense:	'	'	'	'	'
Research and development	$2,973	$4,582	$7,852	$8,779	$130,608
General and administrative	1,859	2,084	4,252	4,230	48,913
Loss from operations	-4,832	-6,666	-12,104	-13,009	-179,521
Other Income (Expense):	'	'	'	'	'
Interest income	2	7	5	19	1,410
Related party interest expense	'	'	'	'	-21,113
Interest expense	'	'	'	'	-952
Interest from amortization of notes payable premium	'	'	'	'	2,283
Change in fair value of preferred stock rights and warrant liabilities	'	'	'	'	1,795
Loss on extinguishment of notes payable	'	'	'	'	-13,285
Other income (expense)	-3	12	-10	12	-62
Net Loss	-4,833	-6,647	-12,109	-12,978	-209,445
Cumulative dividends and deemed dividends on Series H convertible preferred stock	'	'	'	'	-10,695
Net Loss Attributable to Common Stockholders	-4,833	-6,647	-12,109	-12,978	-220,140
Net Loss Per Common Share:	'	'	'	'	'
Net loss per share, basic and diluted (in dollars per share)	($0.14)	($0.20)	($0.36)	($0.39)	'
Shares used to compute net loss per share, basic and diluted (in shares)	33,361,259	33,114,941	33,350,578	33,106,494	'
Comprehensive Loss:	'	'	'	'	'
Net loss	-4,833	-6,647	-12,109	-12,978	-209,445
Cumulative dividends and deemed dividends on Series H convertible preferred stock	'	'	'	'	-10,695
Comprehensive Loss Attributable to Common Stockholders	($4,833)	($6,647)	($12,109)	($12,978)	($220,140)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended		193 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Cash Flows from Operating Activities:	'	'	'
Net loss	($12,109)	($12,978)	($209,445)
Non-cash adjustments to reconcile net loss to net cash used for operating activities:	'	'	'
Depreciation and amortization	525	401	5,387
Loss on property and equipment disposal and impairment	'	1	586
Stock-based compensation	2,184	2,008	14,889
Interest on notes payable	'	'	8,562
Repayment premium on notes payable	'	'	11,100
Loss on change in fair value of preferred stock warrant liability	'	'	970
Gain on change in fair value of preferred stock rights liability	'	'	-2,765
Loss on extinguishment of notes payable	'	'	13,285
Other non-cash expenses	10	9	178
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses and other current assets	98	53	-317
Other assets	'	'	-60
Accounts payable	-506	149	699
Accrued expenses and other current liabilities	-963	-171	1,019
Long-term liabilities	-68	-58	353
Net cash used for operating activities	-10,829	-10,586	-155,559
Cash Flows from Investing Activities:	'	'	'
Purchases of property and equipment	-338	-522	-9,347
Sales of property and equipment	'	'	167
Purchases of investments	'	'	-26,593
Maturities of investments	747	3,235	25,848
Net cash provided by (used for) investing activities	409	2,713	-9,925
Cash Flows from Financing Activities:	'	'	'
Proceeds from issuances of convertible preferred stock, net	'	'	68,917
Proceeds from issuances of common stock	170	19	85,489
Initial public offering costs, net	'	'	-8,068
Proceeds from exercises of warrants	'	'	263
Repurchases of stock	'	'	-638
Proceeds from issuances of notes payable	'	'	28,600
Repayments of notes payable	'	'	-100
Net cash provided by financing activities	170	19	174,463
Net increase (decrease) in cash and cash equivalents	-10,250	-7,854	8,979
Cash and cash equivalents at beginning of period	19,229	38,876	'
Cash and Cash Equivalents at End of Period	8,979	31,022	8,979
Supplemental Cash and Non-Cash information:	'	'	'
Cash paid for interest	'	'	126
Non-cash conversions of notes payable, accrued interest, note premiums and discounts, preferred stock, non-voting common stock, preferred warrants, and common warrants upon initial public offering in December 2010	'	'	120,349
Property and equipment in accounts payable at end of period	$3	$430	$3

Background_Basis_of_Presentati

Background, Basis of Presentation, and Going Concern	6 Months Ended
Background, Basis of Presentation, and Going Concern	Jun. 30, 2014
Background, Basis of Presentation, and Going Concern	'
Background, Basis of Presentation, and Going Concern	'
	1. Background, Basis of Presentation, and Going Concern

	Background: REVA Medical, Inc. (“REVA” or the “Company”) was incorporated in California in 1998 under the name MD3, Inc. In March 2002, we changed our name to REVA Medical, Inc. In October 2010, we reincorporated in Delaware. We established a non-operating wholly owned subsidiary, REVA Germany GmbH, in 2007. In these notes the terms “us,” “we,” or “our” refer to REVA and our consolidated subsidiary unless context dictates otherwise.

	In December 2010, we completed an initial public offering (the “IPO”) of our common stock in Australia. We issued 7,727,273 shares of common stock for gross proceeds of $84.3 million. Our stock is traded in the form of CHESS Depository Interests (“CDIs”) on the Australian Securities Exchange; each share of our common stock is equivalent to ten CDIs. Our trading symbol is “RVA.AX.”

	We are currently developing and testing a bioresorbable stent to treat vascular disease in humans. We do not yet have a product available for sale; our product(s) will become available following completion of required clinical studies with acceptable data and when, and if, we receive regulatory approval. We initiated the first human clinical trial of our bioresorbable stent during 2007, enrolled 26 patients in a second clinical trial between December 2011 and July 2012, and enrolled 112 patients in a third trial between March 2013 and January 2014.

	During the first quarter of 2014, we announced our plans to focus on a stent with a unibody design that is made from our proprietary bioresorbable polymer. Our development and testing are progressing as planned and we anticipate initiating a clinical trial with this new stent by the end of 2014. Concurrent with the first quarter announcement, we made an approximate 45 percent reduction in headcount on March 26, 2014 and reduced other overhead costs. The offers of severance we made in connection with the reductions approximated $415,000 including related payroll taxes, of which $237,000 was recorded as research and development and $178,000 as general and administrative expense as of March 31, 2014. The payouts of severances were made during the second quarter of 2014. We did not incur any other expenses in connection with the change in development focus and headcount reductions.

	Basis of Presentation: We have prepared the accompanying consolidated financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting of interim financial information and, therefore, certain information and footnote disclosures normally included in annual financial statements have been omitted. Accordingly, these interim financial statements should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and with the audited financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2013.

	Our consolidated financial statements include the accounts of REVA and our wholly owned subsidiary. All intercompany transactions and balances, if any, have been eliminated in consolidation. The consolidated balance sheet as of June 30, 2014, the consolidated statements of operations and comprehensive loss and of cash flows for the three and six months ended June 30, 2013 and 2014 and the period from June 3, 1998 (inception) through June 30, 2014 are unaudited. The interim financial statements have been prepared on the same basis as our annual financial statements and, in our opinion, all adjustments, consisting only of normal recurring accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of operations for the six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period.

	Development Stage: We are considered a “development stage” enterprise, as we have not yet generated revenue from the sale of products. Although we have been researching and developing new technologies and product applications and are conducting clinical trials of our bioresorbable stents, we do not anticipate having a product available for sale until we receive regulatory approval to commercialize in Europe (“CE Marking”) or other regulatory approval, which we expect will be mid-2016 at the earliest. Until revenue is generated from a saleable product, we expect to continue to incur substantial operating losses and experience significant net cash outflows.

	Capital Resources: We had cash and investments totaling $9,724,000 as of June 30, 2014, which we believe will be sufficient to fund our operating and capital needs into the first quarter of 2015. We intend to raise additional capital in 2014 through equity or debt financings. There can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. If we are unable to raise sufficient additional capital, we may be compelled to further reduce the scope of our operations and planned capital expenditures or sell certain assets, including our intellectual property assets.

	Going Concern: The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Given our current cash and investment balances and our planned operating activities, our recurring losses and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going concern. Even if we are able to raise additional capital, we may never become profitable, or if we do attain profitable operations, we may not be able to sustain profitability and positive cash flows on a recurring basis.

	Use of Estimates: In order to prepare our financial statements in conformity with GAAP, we are required to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Our most significant estimates relate to operating expense accruals, including preclinical and clinical expenses, and stock-based compensation. Actual results could differ from our estimates.

	Reclassifications: Certain prior year amounts within the consolidated statements of cash flows have been reclassified to conform to the current year presentation. These reclassifications had no impact on the net decreases in cash and cash equivalents as previously reported.

	Recent Accounting Pronouncements: Effective January 1, 2014, we adopted Accounting Standards Update No. 2013-11 (“ASU 2013-11”), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The adoption of ASU 2013-11 did not have an effect on our financial position, results of operations, or related financial statement disclosures.

	In April 2014 ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, was issued and in June 2014 ASU 2014-10, Development Stage Entities: Elimination of Certain Financial Reporting Requirements” was issued. ASU 2014-08 raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures for certain other disposals that do not meet the definition of a discontinued operation. ASU 2014-10 removes financial reporting distinction between development stage entities and other reporting entities. Both these ASUs are effective for REVA beginning January 1, 2015; we do not expect their implementations to have an effect on our financial position or results of operations, but do expect that upon implementation of ASU 2014-10 we will no longer provide “inception to date” disclosures in our financial statements and the related notes thereto.

Balance_Sheet_Details

Balance Sheet Details	6 Months Ended
Balance Sheet Details	Jun. 30, 2014
Balance Sheet Details	'
Balance Sheet Details	'
	2. Balance Sheet Details

	Investments: We invest excess cash in high-quality marketable securities. Our investments are classified as either short- or long-term based on their maturity dates; investments with a maturity of less than one year are classified as short-term and all others are classified as long-term. We have categorized the investments as “held-to-maturity” based on our intent and ability to hold to maturity. Our investments are stated at cost; their fair value is determined each reporting period through quoted market prices of similar instruments in active markets, which is a Level 2 category in the fair value hierarchy according to GAAP. During the reporting period there were no declines in fair value that were deemed to be other than temporary and no transfers between hierarchy levels.

	Investments (continued): Our marketable security investment balances, consisting only of time deposits, are as follows:

		Cost			Gross			Fair Value
					Unrealized
					Losses
		(in thousands)
	As of December 31, 2013:
	Time deposits due in one year or less	$	1,492		$	(4	)	$	1,488

	As of June 30, 2014:
	Time deposits due in one year or less	$	745		$	—		$	745

	Property and Equipment and Accrued Expenses: Components of our property and equipment and accrued expenses and other current liabilities are as follows:

		December 31,			June 30,
		2013			2014
		(in thousands)
	Property and equipment:
	Furniture, office equipment, and software	$	656		$	666
	Laboratory equipment	4,896			4,992
	Leasehold improvements	2,305			2,344
		7,857			8,002
	Accumulated depreciation and amortization	(4,268		)	(4,792		)
		$	3,589		$	3,210

	Accrued expenses and other current liabilities:
	Accrued salaries and other employee costs	$	1,371		$	316
	Accrued operating expenses	560			701
	Accrued use taxes and other	149			110

		$	2,080		$	1,127

Income_Taxes

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2014
Income Taxes	'
Income Taxes	'
	3. Income Taxes

	We have reported net losses for all periods through June 30, 2014; therefore, no provision for income taxes has been recorded since our inception. The net operating loss carryforwards arising from our net losses may be available to offset future taxable income for income tax purposes; however, under Internal Revenue Code (“IRC”) Sections 382 and 383, use of the net operating loss carryforwards, as well as our research tax credit carryforwards, may be limited based on cumulative changes in ownership. We have established a valuation allowance against our net deferred tax assets due to the uncertainty surrounding the realization of those assets and we, therefore, have no deferred asset or liability balance for any reporting period. We periodically evaluate the recoverability of the deferred tax assets and, when it is determined that it is more-likely-than-not that the deferred tax assets are realizable, the valuation allowance will be reduced. Due to our valuation allowance, future changes in our unrecognized tax benefits will not impact our effective tax rate.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Jun. 30, 2014
Stock-Based Compensation	'
Stock-Based Compensation	'
	4. Stock-Based Compensation

	The Plan: Our 2010 Equity Incentive Plan, as amended, was a follow-on to our 2001 Stock Option/Stock Issuance Plan and the two plans are collectively referred to as the “Plan.” The Plan provides for restricted stock awards as well as for grants of incentive and non-qualified stock options for purchase of our common stock at a price per share equal to the closing market price on the date of grant. The number of shares reserved for issuance under the Plan may be increased annually by up to three percent of the outstanding stock of the Company and on January 1, 2014, an additional 998,101 shares were reserved for issuance under the Plan. An aggregate of 7,351,835 shares are reserved for issuance under the Plan as of June 30, 2014. The term of options granted under the Plan may not exceed ten years. Options granted prior to 2010 generally vested over five years, with 20 percent vesting on each annual anniversary of the vesting commencement date. Beginning in 2010, a majority of the options granted vest over four years, with 25 percent vesting on the one-year anniversary of the vesting commencement date and 75 percent in equal monthly installments thereafter. A total of 75,000 options granted in May 2014 provide for vesting over a one-year period, with 25 percent vesting on each three-month anniversary from date of grant. All vesting is subject to continued service to the Company. All of our stock options are exercisable at any time but, if exercised, are subject to a lapsing right of repurchase by us until fully vested, at the exercise price.

	Option activity under the Plan is as follows:
					Weighted
					Average
			Options		Exercise
			Outstanding		Price
	Balance at December 31, 2012		3,550,000		$	7.3
	Granted		589,500		$	5.36
	Cancelled		(42,500	)	$	2
	Exercised		(50,350	)	$	0.61
	Balance at December 31, 2013		4,046,650		$	7.15
	Granted		637,000		$	3.53
	Cancelled		(48,531	)	$	5.84
	Exercised		(189,150	)	$	0.9
	Balance at June 30, 2014		4,445,969		$	6.91

	During July 2012, January 2013, and May 2013 we awarded 33,000 shares, 40,000 shares, and 47,500 shares, respectively, of restricted stock; 25 percent of each award vests on each annual anniversary date of the award.

	No tax benefits arising from stock-based compensation have been recognized in the consolidated statements of operations and comprehensive loss through June 30, 2014.

	Stock Options and Restricted Stock to Employees: We account for option grants and restricted stock awards to employees based on their estimated fair values on the date of grant or award, with the resulting stock-based compensation recorded over the vesting period on a straight-line basis. We include non-employee directors as employees for this purpose. Stock-based compensation arising from employee options and awards under the Plan is as follows (dollars in thousands):

			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2013			2014			2013		2014
	Research and development		$	266		$	285		$	534	$	573
	General and administrative		763			784			1,470		1,562
	Total stock-based compensation		$	1,029		$	1,069		$	2,004	$	2,135

	Stock Options and Restricted Stock to Employees (continued): The fair values of options granted were estimated using the following weighted average assumptions:

			Six Months Ended
			June 30,
			2013		2014
	Risk-free interest rate		1.38	%	2.33	%
	Expected volatility of common stock		60.1	%	59.3	%
	Expected life — years		6.25		6.14
	Dividend yield		0.0	%	0.0	%

	The assumed risk-free interest rate was based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term equal to the expected life of the option. The assumed volatility was calculated from the historical market prices of a selected group of publicly traded companies considered to be our peers; we use peer group data due to the fact that we have limited historical trading data. The expected option life was calculated using the simplified method under the accounting standard for stock compensation and a ten-year option expiration; we use the simplified method because we do not yet have adequate history as a public company to establish a reasonable expected life. The expected dividend yield of zero reflects that we have not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future. The options granted to employees during the six months ended June 30, 2014 had a weighted average grant date fair value of $1.98.

	The fair value of our restricted stock awards is calculated using the closing market price on the date of award.

	The aggregate intrinsic value of options exercised during the six months ended June 30, 2013 and 2014 was $142,000 and $557,000, respectively.

	Stock Options to Consultants: We account for stock options granted to consultants at their fair value. Under this method, the fair value is estimated at each reporting date during the vesting period using the Black-Scholes option-pricing model. The resulting stock-based compensation expense, or income if the fair value declines in a reporting period, is recorded over the consultant’s service period. Options to purchase 110,000 shares of common stock were granted to consultants during the six months ended June 30, 2014. No options were granted to consultants during the six months ended June 30, 2013. Stock-based compensation expense or (income) arising from consultant options granted under the Plan is as follows (dollars in thousands):

			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2013			2014			2013		2014
	Research and development		$	(3	)	$	(6	)	$	4	$	73
	General and administrative		—			(20		)	—		(24		)
	Total stock-based compensation		$	(3	)	$	(26	)	$	4	$	49

	Stock Options to Consultants (continued): The weighted-average fair value of unvested consultant options at June 30, 2013 and 2014 was estimated to be $4.05 and $0.58 per share, respectively, based on the following weighted-average assumptions:

			Six Months Ended
			June 30,
			2013		2014
	Risk-free interest rate		1.96	%	2.53	%
Expected volatility of common stock		60.1	%	59.1	%
Expected life — years		6.21		9.20
Dividend yield		0.0	%	0.0	%

The assumed risk-free interest rate was based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term equal to the expected life of the option. The assumed volatility was calculated from the historical market prices of a selected group of publicly traded companies considered to be our peers; we use peer group data due to the fact that we have limited historical trading data. The expected option life is the remaining term of the option. The expected dividend yield of zero reflects that we have not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2014
Commitments and Contingencies.	'
Commitments and Contingencies	'
	5. Commitments and Contingencies

	We have licensed certain patents and other intellectual property rights related to the composition and coating of our bioresorbable stent and our other biomaterial products. Terms of these licenses include provisions for royalty payments on any future sales of products, if any, utilizing this technology, with provisions for minimum royalties once product sales begin. The amount of royalties varies depending upon type of product, use of product, stage of product, location of sale, and ultimate sales volume, and ranges from a minimum of approximately $25 per unit to a maximum of approximately $100 per unit sold, with license provisions for escalating minimum royalties that could be as high as $2.2 million per year. Additionally, in the event we sublicense the technology and receive certain milestone payments, the licenses require that up to 40 percent of the milestone amount be paid to the licensors. Additional terms of the technology licenses include annual licensing payments of $175,000 until the underlying technology has been commercialized; the $175,000 for 2014 was paid and recorded to research and development expense during the first quarter of 2014. Terms of the licenses also include other payments to occur during commercialization that could total $950,000, payment of $350,000 upon a change in control of ownership, payments of up to $300,000 annually to extend filing periods related to certain technology, and payment of patent filing, maintenance, and defense fees. The license terms remain in effect until the last patent expires.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	6 Months Ended
Net Loss Per Common Share	Jun. 30, 2014
Net Loss Per Common Share	'
Net Loss Per Common Share	'
	6. Net Loss Per Common Share

	Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method, as applicable. For purpose of this calculation, common stock options and restricted stock subject to forfeiture are considered to be common stock equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive. For the six months ended June 30, 2013 and 2014, common stock options totaling 3,801,198 and 4,372,103 shares, respectively, and restricted stock subject to forfeiture totaling 79,450 and 100,803 shares, respectively, were excluded from the computation of diluted net loss per share because including them would have been antidilutive.

Background_Basis_of_Presentati1

Background, Basis of Presentation, and Going Concern (Policies)	6 Months Ended
	Jun. 30, 2014
Background, Basis of Presentation, and Going Concern	'
Basis of Presentation	'
	Basis of Presentation: We have prepared the accompanying consolidated financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting of interim financial information and, therefore, certain information and footnote disclosures normally included in annual financial statements have been omitted. Accordingly, these interim financial statements should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and with the audited financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2013.

	Our consolidated financial statements include the accounts of REVA and our wholly owned subsidiary. All intercompany transactions and balances, if any, have been eliminated in consolidation. The consolidated balance sheet as of June 30, 2014, the consolidated statements of operations and comprehensive loss and of cash flows for the three and six months ended June 30, 2013 and 2014 and the period from June 3, 1998 (inception) through June 30, 2014 are unaudited. The interim financial statements have been prepared on the same basis as our annual financial statements and, in our opinion, all adjustments, consisting only of normal recurring accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of operations for the six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period.

Development Stage	'
	Development Stage: We are considered a “development stage” enterprise, as we have not yet generated revenue from the sale of products. Although we have been researching and developing new technologies and product applications and are conducting clinical trials of our bioresorbable stents, we do not anticipate having a product available for sale until we receive regulatory approval to commercialize in Europe (“CE Marking”) or other regulatory approval, which we expect will be mid-2016 at the earliest. Until revenue is generated from a saleable product, we expect to continue to incur substantial operating losses and experience significant net cash outflows.

Capital Resources	'
	Capital Resources: We had cash and investments totaling $9,724,000 as of June 30, 2014, which we believe will be sufficient to fund our operating and capital needs into the first quarter of 2015. We intend to raise additional capital in 2014 through equity or debt financings. There can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. If we are unable to raise sufficient additional capital, we may be compelled to further reduce the scope of our operations and planned capital expenditures or sell certain assets, including our intellectual property assets.

Going Concern	'
	Going Concern: The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Given our current cash and investment balances and our planned operating activities, our recurring losses and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going concern. Even if we are able to raise additional capital, we may never become profitable, or if we do attain profitable operations, we may not be able to sustain profitability and positive cash flows on a recurring basis.

Use of Estimates	'
	Use of Estimates: In order to prepare our financial statements in conformity with GAAP, we are required to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Our most significant estimates relate to operating expense accruals, including preclinical and clinical expenses, and stock-based compensation. Actual results could differ from our estimates.

Reclassifications	'
	Reclassifications: Certain prior year amounts within the consolidated statements of cash flows have been reclassified to conform to the current year presentation. These reclassifications had no impact on the net decreases in cash and cash equivalents as previously reported.

Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements: Effective January 1, 2014, we adopted Accounting Standards Update No. 2013-11 (“ASU 2013-11”), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The adoption of ASU 2013-11 did not have an effect on our financial position, results of operations, or related financial statement disclosures.

	In April 2014 ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, was issued and in June 2014 ASU 2014-10, Development Stage Entities: Elimination of Certain Financial Reporting Requirements” was issued. ASU 2014-08 raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures for certain other disposals that do not meet the definition of a discontinued operation. ASU 2014-10 removes financial reporting distinction between development stage entities and other reporting entities. Both these ASUs are effective for REVA beginning January 1, 2015; we do not expect their implementations to have an effect on our financial position or results of operations, but do expect that upon implementation of ASU 2014-10 we will no longer provide “inception to date” disclosures in our financial statements and the related notes thereto.

Balance_Sheet_Details_Tables

Balance Sheet Details (Tables)	6 Months Ended
Balance Sheet Details (Tables)	Jun. 30, 2014
Balance Sheet Details	'
Schedule of marketable security investment balances grouped as time deposits	'
		Cost			Gross			Fair Value
					Unrealized
					Losses
		(in thousands)
	As of December 31, 2013:
	Time deposits due in one year or less	$	1,492		$	(4	)	$	1,488

	As of June 30, 2014:
	Time deposits due in one year or less	$	745		$	—		$	745


Schedule of components of property and equipment	'

		December 31,			June 30,
		2013			2014
		(in thousands)
	Property and equipment:
	Furniture, office equipment, and software	$	656		$	666
	Laboratory equipment	4,896			4,992
	Leasehold improvements	2,305			2,344
		7,857			8,002
	Accumulated depreciation and amortization	(4,268		)	(4,792		)
		$	3,589		$	3,210

	Accrued expenses and other current liabilities:
	Accrued salaries and other employee costs	$	1,371		$	316
	Accrued operating expenses	560			701
	Accrued use taxes and other	149			110

		$	2,080		$	1,127

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
Stock-Based Compensation (Tables)	Jun. 30, 2014
Stock-Based Compensation	'
Schedule of the option activity under the plan	'
				Weighted
				Average
		Options		Exercise
		Outstanding		Price
	Balance at December 31, 2012	3,550,000		$	7.3
	Granted	589,500		$	5.36
	Cancelled	(42,500	)	$	2
	Exercised	(50,350	)	$	0.61
	Balance at December 31, 2013	4,046,650		$	7.15
	Granted	637,000		$	3.53
	Cancelled	(48,531	)	$	5.84
	Exercised	(189,150	)	$	0.9
	Balance at June 30, 2014	4,445,969		$	6.91


Options Granted [Member]	'
Stock-Based Compensation	'
Schedule of the expense (income) recorded under the plan	'
	Stock-based compensation arising from employee options and awards under the Plan is as follows (dollars in thousands):

		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013		2014
	Research and development	$	266		$	285		$	534	$	573
	General and administrative	763			784			1,470		1,562
	Total stock-based compensation	$	1,029		$	1,069		$	2,004	$	2,135


Schedule of the weighted-average assumptions used to estimate fair value of options granted	'
		Six Months Ended
		June 30,
		2013		2014
	Risk-free interest rate	1.38	%	2.33	%
	Expected volatility of common stock	60.1	%	59.3	%
	Expected life — years	6.25		6.14
	Dividend yield	0.0	%	0.0	%


Stock Options To Consultants [Member]	'
Stock-Based Compensation	'
Schedule of the expense (income) recorded under the plan	'
	Stock-based compensation expense or (income) arising from consultant options granted under the Plan is as follows (dollars in thousands):

		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2013			2014			2013		2014
	Research and development	$	(3	)	$	(6	)	$	4	$	73
	General and administrative	—			(20		)	—		(24		)
	Total stock-based compensation	$	(3	)	$	(26	)	$	4	$	49


Schedule of the weighted-average assumptions used to estimate fair value of options granted	'
		Six Months Ended
		June 30,
		2013		2014
	Risk-free interest rate	1.96	%	2.53	%
	Expected volatility of common stock	60.1	%	59.1	%
	Expected life — years	6.21		9.20
	Dividend yield	0.0	%	0.0	%

Background_Basis_of_Presentati2

Background, Basis of Presentation, and Going Concern (Details) (USD $)	1 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2010
Basis of Presentation	'
Common stock to CDIs conversion ratio	10
Common Class A [Member]	'
Basis of Presentation	'
Common Stock issued	7,727,273
Gross proceed of common stock	$84.30

Background_Basis_of_Presentati3

Background, Basis of Presentation, and Going Concern (Details 2) (USD $)	0 Months Ended	6 Months Ended
	Mar. 26, 2014	Jun. 30, 2014
Background, basis of presentation, and going concern	'	'
Reduction in headcount (as a percent)	45.00%	'
Severance costs	'	$415,000
Capital Resources	'	'
Cash and investments	'	9,724,000
Research And Development Expense [Member]	'	'
Background, basis of presentation, and going concern	'	'
Severance costs	'	237,000
General And Administrative Expense [Member]	'	'
Background, basis of presentation, and going concern	'	'
Severance costs	'	$178,000
Second Human Clinical Trial [Member]	'	'
Background, basis of presentation, and going concern	'	'
Number of patients enrolled in a clinical trial of bioresorbable stent product	'	26
Third Human Clinical Trial [Member]	'	'
Background, basis of presentation, and going concern	'	'
Number of patients enrolled in a clinical trial of bioresorbable stent product	'	112

Balance_Sheet_Details_Details

Balance Sheet Details (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Jun. 30, 2014
Balance Sheet Details	'	'
Cost, one year or less	$1,492	$745
Gross Unrealized loss	-4	'
Fair Value	$1,488	$745

Balance_Sheet_Details_Details_

Balance Sheet Details (Details 2) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Property and equipment:	'	'
Property and equipment, gross	$8,002	$7,857
Accumulated depreciation and amortization	-4,792	-4,268
Property and equipment, net	3,210	3,589
Office Equipment [Member]	'	'
Property and equipment:	'	'
Property and equipment, gross	666	656
Equipment [Member]	'	'
Property and equipment:	'	'
Property and equipment, gross	4,992	4,896
Leasehold Improvements [Member]	'	'
Property and equipment:	'	'
Property and equipment, gross	$2,344	$2,305

Balance_Sheet_Details_Details_1

Balance Sheet Details (Details 3) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Accrued expenses and other current liabilities:	'	'
Accrued salaries and other employee costs	$316	$1,371
Accrued operating expenses	701	560
Accrued use taxes and other	110	149
Accrued expenses and other current liabilities, total	$1,127	$2,080

Income_Taxes_Details

Income Taxes (Details) (USD $)	6 Months Ended
Income Taxes (Details) (USD $)	Jun. 30, 2014
Income Taxes	'
Provision for income taxes	$0
Deferred tax assets	0
Deferred tax liability	$0

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)

6 Months Ended

0 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

Jun. 30, 2014

Jan. 02, 2014

Jun. 30, 2014

Dec. 31, 2013

Jan. 31, 2013

Jul. 31, 2012

31-May-13

Jun. 30, 2014

31-May-14

Employee Stock Option [Member]

Equity Incentive Plan2010 And Stock Option And Stock Issuance Plan2001 Plan [Member]

Stock Option And Stock Issuance Plan2001 Plan [Member]

Equity Incentive Plan2010 [Member]

plan

Maximum [Member]

Employee Stock Option [Member]

Restricted Stock Second Award [Member]

Restricted Stock First Award [Member]

Employee Stock Option [Member]

Stock-Based Compensation

Number of plans covered under stock-based compensation arrangement

Increment in the number of shares reserved under the Plan annually (as a percent)

3.00%

Number of shares added in reserve

998,101

Total number of shares in reserve with additional shares under the Plan

7,351,835

Term of options granted under the plan

'10 years

Vesting periods

'5 years

'4 years

'1 year

Vesting percentage

20.00%

25.00%

Options Outstanding

Balance at the beginning of period (in shares)

4,046,650

3,550,000

Granted (in shares)

637,000

589,500

75,000

Cancelled (in shares)

-48,531

-42,500

Exercised (in shares)

-189,150

-50,350

Balance at the end of period (in shares)

4,445,969

4,046,650

Weighted Average Exercise Price

Balance at the beginning of period (in dollars per share)

$7.15

$7.30

Granted (in dollars per share)

$3.53

$5.36

Cancelled (in dollars per share)

$5.84

Exercised (in dollars per share)

$0.90

$0.61

Balance at the end of period (in dollars per share)

$6.91

$7.15

Number of shares awarded

40,000

33,000

47,500

Annual vesting percent

25.00%

Tax benefits from stock based compensation

Term of options granted under the plan

'3 months

Percentage of remaining option grants vesting in equal monthly installments after the one-year anniversary of the vesting commencement date

75.00%

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (Stock Awards And Option Grants [Member], USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock Options and Restricted Stock to Employees	'	'	'	'
Total stock-based compensation	$1,069	$1,029	$2,135	$2,004
Research And Development Expense [Member]	'	'	'	'
Stock Options and Restricted Stock to Employees	'	'	'	'
Total stock-based compensation	285	266	573	534
General And Administrative Expense [Member]	'	'	'	'
Stock Options and Restricted Stock to Employees	'	'	'	'
Total stock-based compensation	$784	$763	$1,562	$1,470

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 3) (USD $)	3 Months Ended		6 Months Ended
Stock-Based Compensation (Details 3) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Stock Option [Member]	'	'	'	'
Additional information related to fair values of options granted	'	'	'	'
Risk-free interest rate (as a percent)	'	'	2.33%	1.38%
Expected volatility of common stock (as a percent)	'	'	59.30%	60.10%
Expected life	'	'	'6 years 1 month 21 days	'6 years 3 months
Dividend yield (as a percent)	'	'	0.00%	0.00%
Expiration term	'	'	'10 years	'
Weighted average grant date fair value (in dollars per share)	'	'	$1.98	'
Intrinsic value of options exercised	'	'	$557,000	$142,000
Stock Options To Consultants [Member]	'	'	'	'
Additional information related to fair values of options granted	'	'	'	'
Risk-free interest rate (as a percent)	'	'	2.53%	1.96%
Expected volatility of common stock (as a percent)	'	'	59.10%	60.10%
Expected life	'	'	'9 years 2 months 12 days	'6 years 2 months 16 days
Dividend yield (as a percent)	'	'	0.00%	0.00%
Weighted average grant date fair value (in dollars per share)	'	'	$0.58	$4.05
Granted (in shares)	'	'	110,000	'
Total stock-based compensation	-26,000	-3,000	49,000	4,000
Stock Options To Consultants [Member] \| Research And Development Expense [Member]	'	'	'	'
Additional information related to fair values of options granted	'	'	'	'
Total stock-based compensation	-6,000	-3,000	73,000	4,000
Stock Options To Consultants [Member] \| General And Administrative Expense [Member]	'	'	'	'
Additional information related to fair values of options granted	'	'	'	'
Total stock-based compensation	($20,000)	'	($24,000)	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	6 Months Ended
Commitments and Contingencies (Details) (USD $)	Jun. 30, 2014
Commitment and Contingencies	'
License provisions for escalating minimum royalties	$2,200,000
Annual licensing payment	175,000
Other payments of royalty agreement occur during commercialization	950,000
Payment due to change in control of ownership	350,000
Minimum [Member]	'
Commitment and Contingencies	'
Royalty payment per unit (in dollar per unit)	25
Maximum [Member]	'
Commitment and Contingencies	'
Royalty payment per unit (in dollar per unit)	100
Milestone amounts paid to the licensors (as a percent)	40.00%
Annual payments to extend filing periods related to certain technology	$300,000

Net_Loss_Per_Common_Share_Deta

Net Loss Per Common Share (Details)	6 Months Ended
Net Loss Per Common Share (Details)	Jun. 30, 2014	Jun. 30, 2013
Employee Stock Option [Member]	'	'
Net Income Loss Per Common Share	'	'
Securities excluded from the computation of diluted net loss per share (in shares)	4,372,103	3,801,198
Restricted Stock [Member]	'	'
Net Income Loss Per Common Share	'	'
Securities excluded from the computation of diluted net loss per share (in shares)	100,803	79,450